Close Menu

retinitis pigmentosa

In Science this week: platform to diagnose genetic disease in children, lung disease-causing genetic mutation corrected in mice, and more.

To study the benefit of genetic testing data, the Foundation Fighting Blindness offered free clinical testing to 100 members of its My Retina Tracker patient registry.

In Nature this week: 3D genome structures, CRISPR approach prevents retinitis pigmentosa in mice, and more.

A blind woman in Texas has been treated with an optogenetic therapy, Technology Review reports.

For several reasons, scientists, as well as gene editing therapy company Editas, think that the first clinical trials for CRISPR-based cures will be for hereditary eye diseases.

The study hints that iPSCs derived from patients with the hereditary disease could be edited ex vivo and reintroduced to fix damaged retinas.

Genable Technologies, an Irish biopharmaceutical firm, announced last week that it has received orphan drug status from the US Food and Drug Administration for its expressed RNAi-based treatment for retinitis pigmentosa.

Irish biopharmaceutical firm Genable Technologies announced this week that it has acquired an exclusive, worldwide license to Benitec Biopharma's expressed RNAi technology for use in a treatment for the rare ocular disease rhodopsin-linked autosomal dominant retinitis pigmentosa.

The newly named Washington University Genome Institute intends to move beyond research-oriented sequencing projects and toward those with a clinical bent.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.